UOC Pharmacy

The UOC Farmacia is a structure whose main objective is to guarantee uniformity throughout the Company’s territory in (affiliated) pharmaceutical care both at the territorial and hospital level. It represents a tool for balance and coordination between the operational and organisational units, on the one hand to guarantee the quality of the provision of services and on the other to encourage the design capacity to achieve the objective of qualification of pharmaceutical expenditure. A specific and particularly complex institutional task of the structure is the supervision, control and management of the safety of drugs and medical-diagnostic devices.

The facility is also the ideal location for staff training and refresher courses.

In summary, the priority objectives of the Pharmacy UOC are:

  • promotion of the appropriateness of pharmaceutical prescriptions and consumption, through training activities and sending reports and information material to General Practitioners and Paediatricians of Free Choice;
  • rationalization of direct and contracted external pharmaceutical spending, through the homogenization of prescribing behaviors, both in the hospital and territorial context, through the increase of adherence to the Therapeutic Handbook, the shared Guidelines and the authorized therapeutic indications of the AIFA;
  • reduction of the risks of damage to health, deriving from errors in the prescription/administration of drugs or from adverse reactions and/or inappropriate treatments, through constant checks of adherence to therapeutic schedules/protocols, relevance to the methods of administration and any interaction and/or incompatibility;
  • rationalisation of logistics, in the purchasing and distribution process, through critical review of warehouse management, development of computerisation throughout the management cycle of health assets;
  • implementation of new methods of direct distribution of drugs, in order to make it more efficient and appropriate and allow, at the same time, the operation of continuity of care (direct distribution of drugs of the first cycle of therapy…);
  • capillary and routine activities aimed at training/information on the use and characteristics of drugs and devices, aimed at all health professionals;
  • design and conduct of drug use studies, in order to improve knowledge at the territorial level, as well as to compare the results with the scientific literature and with different territorial realities.

Services/Activities provided

Drug information activities

  • information and scientific documentation to health personnel and citizens;
  • design and conduct of drug epidemiology studies and management of particular protocols aimed at studying the risk/benefit ratio in the use of drugs;
  • information on pharmaceutical legislation;
  • promotion of the correct use of the drug;
  • health information and education for the population or community (schools, factories, etc…);
  • technical support and Technical-Scientific Secretariats of
    • Hospital and territorial company therapeutic commission (PTOTA);
    • Trials Office (Company headquarters in liaison with the Ethics Committee);
    • Committee for the fight against Hospital Infections (CICCA);
    • Company Observatory for Prescriptive Appropriateness;
    • Commission for the Directory of Medical Devices;
    • Commission for non-fungibility;
    • Company Pharmaceutical Commission

Affiliated Pharmaceutical Business

  • management of conventional relationships with Pharmacies and verification of the application of Presidential Decree 371/98 and its additions (release of codes, acquisition of recipes, reconciliation of the online DCR system, management of anomalies and corrections);
  • management of pharmacy records (SOGEI/DCR online);
  • dGR application control no. 16 of 16.01.2009 on commercial establishments authorised for food trade and parapharmacies authorised by the ASL for the supply of gluten-free products; acquisition of vouchers and liquidation;
  • preparation of information flows (Article 50 of Law 326/2003 – TS System);
  • monitoring (regional DWH) consumption data and by type of delivery;
  • processing and management of data related to the agreed pharmaceutical expenditure;
  • scheduled information to prescribers and affiliated pharmacies;
  • elaboration of intervention programs for the rationalization of the agreed pharmaceutical expenditure (Report – National Indicators Legislative Decree 78/2010 and Regional);
  • information to users on the prescribability of drugs, application of tickets, exemptions, etc.;
  • information to prescribers on how to prescribe medicines;
  • pharmacoepidemiology in the territory;
  • analysis of consumption and expenditure data by territory/general practitioner/assisted… other;
  • studies and research aimed at specific pharmacological and pharmacoeconomic problems;
  • creation of evidence on prescriptive and/or dispensing anomalies;
  • promotion of activities aimed at the implementation of protocols and agreements involving pharmaceutical assistance in agreement and the relationship with health prescribers;
  • technical support to the Company Pharmaceutical Commission (Presidential Decree 371/98);
  • verification activities on prescriptive appropriateness (MMG and PLS Agreement);
  • support for trials of GMMs and/or PLSs;
  • information and scientific documentation to Health and support personnel;
  • conducting pharmacoepidemiology studies;
  • information on pharmaceutical legislation;
  • technical support and research, active participation in: Company Therapeutic Commission (PTOTA) – Trials Office – District Prescriptive Appropriateness Commissions (CAPD) – Observatory for Prescriptive Appropriateness;
  • participation and inspection commissions for the verification of prescriptive appropriateness at the District Pharmacies (Presidential Decree 371/98).

Pharmacovigilance activities

  • transposition, monitoring and sending of reports of adverse drug reactions;
  • processing of data for epidemiological purposes;
  • production and dissemination of information reports to the company’s healthcare professionals (employees and affiliates);
  • awareness-raising activities to report adverse reactions (doctors and pharmacies);
  • support and management of the Trial Office, with monitoring of adverse reactions and the progress of the Protocols;
  • drafting of FARMAINFORMA, information note on drugs and pharmacovigilance, published monthly or with special issues on the ASL website (https://www.asl.fr.it/farmainforma-news)

Flow management/analysis activities (expected as LEA fulfillment)

  • detection and monitoring of consumption flows (Flow R – FARMED – Disp.Medici – WEBCARE – OncoAIFA – other);
  • verification of deviations on the management of health assets;
  • monitoring of the use of health goods for Cost Centres

Hospital Pharmaceutical Activity

Medication Management

  • pre-packaged industrial and generic galenic medicinal products;
  • narcotic and psychotropic substances;
  • serums and vaccines;
  • blood products;
  • large volume infusion solutions;
  • dialysis solutions;
  • contrast media;
  • therapeutic gases;
  • radiopharmaceuticals

Device, Food and Reagent Management

  • medical devices;
  • accessories of pharmaceutical relevance;
  • in vitro diagnostic devices;
  • bespoke devices;
  • devices for clinical investigations and reagents;
  • special foods for therapeutic purposes

Management of Traditional and Clinical Galenics (UFA)

  • own production of medicinal and master-derived galenic preparations reported in the Italian Official Pharmacopoeia (also in series);
  • preparation of impromptu master galenic preparations on specific medical prescription;
  • own preparation of laboratory reagents;
  • preparation of experimental formulations;
  • preparation of infusion mixtures;
  • preparation of preparations for Total Parenteral Nutrition (TPN) both in the hospital and in the territory (not yet active);
  • preparation of anti-blastic chemotherapy – UFA (in the start-up phase);
  • computerised management of AIFA monitoring for the appropriateness of use and application of economic recovery systems

Hospital Pharmacy Activities, relating to Logistics Distribution

  • issuing orders;
  • incoming material reception;
  • qualitative-quantitative checks on the products upon receipt;
  • warehouse management for ordinary products;
  • medical gas storage management;
  • flammable warehouse management;
  • management of products in transit (radiopharmaceuticals, in vitro diagnostics, etc…);
  • management of psychotropic narcotic drugs in hospitals and for the territorial structures of the Company (SERT) and/or entitled to supply;
  • management of extra PTO-PTOR drugs;
  • planned management of high-cost products;
  • management of deliveries to Cost Centres;
  • loading/unloading at the various Cost Centres;
  • consumption analysis;
  • analysis of expenditure;
  • feeding of computerised flows on a national/regional platform (Flow R – Farmed – Ministerial Decree – HOSP – Law 648/96 – OncoAIFA – other)

Surveillance and Pharmacovigilance activities in the Hospital field through

  • inspections of the Department’s pharmaceutical cabinets and internal outpatient facilities;
  • monitoring of drug therapies (therapeutic risk) and adherence to ministerial recommendations;
  • activities regulated by Pharmacovigilance regulations in the Hospital field;
  • information and scientific documentation to hospital doctors and to the non-medical health body of the Hospital;
  • hospital pharmacoepidemiology;
  • information on pharmaceutical legislation;
  • technical support to: Hospital Therapeutic Commission (C.T.A.) – Hospital Infections Committee (CICCA) – Prescriptive Appropriateness Observatory;
  • support for the preparation of the Directory of Headmasters;
  • support for the preparation of the Reagent Directory;
  • participation in the Committees for the Good Use of Blood;
  • relationship with SIO and Management Control to check the information flow and for controls on the appropriateness of the use of drugs in relation to diseases and DRGs;
  • coordination and verification of the activities carried out by the peripheral UUOOs, in relation to the management of the drugs and products of competence.

In the District, the following activities are ensured:

  • supply of medicines and products for assistance to citizens, to the facilities identified by DRG 34/02 as well as to Prison Institutions;
  • direct management of supplementary assistance;
  • supply of products for patients suffering from cystic fibrosis and rare diseases;
  • drug dispensing Law 648/96;
  • long-term home oxygen therapy;
  • supply of products for integrated home care;
  • home artificial nutrition (Del. G.R. Lazio no. 7872 of 11.10.1994);
  • supply of products for nephropathic patients and for patients on Dialysis;
  • analysis of consumption and expenditure;
  • definition of the needs and preparation of the technical specifications of the pharmaceutical assets managed and supply and distribution of pharmaceutical products to all the outpatient facilities of the USL Company;
  • keeping records of Therapeutic Plans and entering them on computerised platforms;
  • management of computerised platforms (Farmed – Webcare – HOSP – Law 648/96 – other);
  • supervision of professional practice and certifications of service,suitability, ownership, etc.;
  • supervision of Pharmacies – Parapharmacies – other exercises managing the drug;
  • supervision of structures outside the AUSL and on affiliated and non-affiliated structures;
  • authorization activities of wholesalers and warehouses of medicines;
  • opinion on the review of the organic plant of the Pharmacies;
  • authorisation to open/operate a Pharmacy and forfeiture of the same;
  • authorization for provisional and hereditary management;
  • authorisation to transfer the premises of the Pharmacy;
  • authorisation for temporary replacements of the holder;
  • temporary closure of the pharmaceutical business;
  • preparation of schedules, shifts and pharmacies holidays;
  • residence allowance in favour of Rural Pharmacies;
  • keeping and managing the register of Pharmacy owners/directors/collaborators and practitioners;
  • detection, custody of drugs that can no longer be used;
  • endorsement and control of drug loading and unloading registers.

How to

Recipients

The recipients are:

  • all the Company Diagnosis and Care, Hospital and Territorial scores;
  • accredited private facilities (RSA – Hospice – Hemodialysis Centers – etc.);
  • penal institutions;
  • private users for Direct Distribution;
  • pharmacies/parapharmacies/establishments for the distribution of products for coeliacs/warehouses/warehouses for the activities of supervision and management of the affiliated pharmaceutical expenditure;
  • exercises for the distribution of products for coeliacs for the monitoring and settlement of skills;
  • general practitioners/paediatricians of free choice/employees/affiliated for the monitoring and management of the affiliated pharmaceutical expenditure.

How to access

User access for Direct Drug Distribution:

by showing the health card and the prescription issued by the Centres identified by the Lazio Region or by the Extra-regional Centres authorised at the UOC headquarters.

Access to pharmacies (affiliated pharmaceutical companies):

opening for delivery and acquisition of prescriptions in the first 10 days of each month at the following times: 9:00 – 13:30 and 14:30 – 16:00, c/o Direction UOC Pharmacy Via A. Fabi Palazzina Q Piano I.

Access to parapharmacies/Exercises for the distribution of products for coeliacs:

opening for delivery and acquisition of prescriptions in the first 3 days of each month at the following times: 9:00 – 13:30 and 14:30 – 16:00, c/o Direction UOC Pharmacy Via A. Fabi Palazzina Q Piano I.

Access to the Management of the Facility:

for the activities of supervision and monitoring/management of the affiliated pharmaceutical expenditure or for authorization activities or for information: from Monday to Friday from 9:00 to 13:00 at the Management of the structure, via A. Fabi Palazzina Q Piano I.

Reception Time

  • Frosinone Hospital Pharmacy: Monday, Wednesday, Friday 09.00 – 13.00;
  • Alatri Hospital Pharmacy: Tuesday, Thursday 09.00 – 15.00;
  • Anagni Hospital Pharmacy: Thursday 09.00 – 13.00;
  • Sora Hospital Pharmacy: Monday, Wednesday, Friday 09.00 – 12.00;
  • Cassino Hospital Pharmacy: Monday, Wednesday, Friday 09.00 – 13.00; Wednesday 15.00 – 17.00;
  • Pharmacy Casa della Salute Pontecorvo: Monday to Friday 10.00 – 13.00.

How to report an adverse drug reaction?

As described in detail on the Company’s website at https://www.asl.fr.it/farmacovigilanza, the reporting of a suspected adverse reaction to the drug, of any level of severity, can be carried out by any citizen by filling out a form downloadable from the website http://www.agenziafarmaco.gov.it/it/content/modalit%C3%AO.

For healthcare professionals, the card is also available on the website https://www.asl.fr.it/farmacovigilanza.

After completion, the report form must be sent to the address farmacovigilanza@aslfrosinone.it or uocfarmacia@aslfrosinone.it.

Alternatively, the report can be made directly online through the platform http://www.vigifarmaco.it.

Back to top

How to report defects/accidents from medical-diagnostic devices?

As described in detail on the Company website at https://www.asl.fr.it/farmacovigilanza, the reporting of defects/accidents from medical devices or complaints to the company can be made by healthcare professionals by filling in a form downloadable from the ASL website at https://www.asl.fr.it/farmacovigilanza.

After completion, the report form must be sent to our facility (uocfarmacia@aslfrosinone.it)which sends it to the Ministry of Health (dgfdm@postacert.sanita.it).

Alternatively, the report can be made directly online through the platform http://www.vigifarmaco.it.

Other information is already available on the company website and on the company portal in the appropriate section powered by the UOC Pharmacy.

Back to top

Contacts

Director: Dr. Fulvio Ferrante

Frosinone Headquarters Management

  • Address: Via A. Fabi, Palazzina Q, I° Piano – 03100 Frosinone
  • Phone: 0775.8822306 – 0775.8822304
  • Email: uocfarmacia@aslfrosinone.it
  • Certified email: farmaconv@pec.aslfrosinone.it
  • Certified email: farmamonitor@pec.aslfrosinone.it
Pharmacovigilance Office
  • Contact person: Dr. Fulvio Ferrante
  • Phone: 0775.8822306
  • Email: farmacovigilanza@aslfrosinone.it
Subsidiary Pharmaceuticals – Flow Management
  • Contact person: Dr. Sabrina Crescenzi
  • Phone: 0775.8822306 – 0775.8822303
  • Email: sabrina.crescenzi@aslfrosinone.it
PTOTA Secretariat
  • Contact person: Dr. Rocco Massimiliano Folcarelli
  • Phone: 0775.8822306
  • Email: uocfarmacia@aslfrosinone.it
Medical Devices Directory – Product Registry – Flow Management
  • Contact person: Dr Patrizia Filomena Venditti
  • Phone: 0775.8822306 – 0775.8822308
  • Email: patriziafilomena.venditti@ aslfrosinone.it

Frosinone Hospital Office

  • Contact person: Dr Cinzia Papetti
  • Directors: Dr. Paola Incitti – Dr. Lucio Carfagna – Dr. Daniela Tomeo
  • Address: F. Spaziani Hospital, Via A. Fabi – 03100 Frosinone
  • Phone: 0775.1883494
  • Email: farmaciab@aslfrosinone.it

Alatri Headquarters

  • Address: San Benedetto Hospital, Loc. Chiappitto – 03011 Alatri
  • Phone: 0775.4385112 – 0775.4385038 – 0775.4385111
  • Email: farmaciaa@aslfrosinone.it

Anagni Headquarters

  • Contact person: Dr. Luigi Miledi
  • Directors: Dr. Emilia Scotti – Dr. Daniela De Falco
  • Address: Former Civil Hospital – 03012 Anagni
  • Phone: 0775.7325278
  • Email: farmaciaa@aslfrosinone.it

Sora Office

  • Contact person: Dr. Daniela Mstroianni
  • Directors: Dr. Loretta Conflitti
  • Address: SS Trinità Hospital, Via S. Marciano – 03039 Sora
  • Phone: 0776.8294040 – 0776.8294038
  • Email: farmaac@aslfrosinone.it

Cassino Office

  • Address: Santa Scolastica Hospital, Via San Pasquale – 03043 Cassino
  • Phone: 0776.3929016 – 0776.3929205
  • Email: farmaad@aslfrosinone.it

Pontecorvo Headquarters Casa della Salute

  • Contact person: Dr. Rocco Massimiliano Folcarelli
  • Directors: Dr. Antonella Petrucci – Dr. Raffaele Pannone
  • Address: Casa della Salute Pontecorvo, Via San Giovanni Mattista – 03037 Pontecorvo
  • Telephone: 0776.7692926
  • Email: farmaad@aslfrosinone.it
Apri pdf
Determinazione G15581 del 21.11.2024

972.61 KB

972.61 KB
Apri pdf
Determinazione G13988 del 22.10.2024

969.75 KB

969.75 KB
Apri pdf
Determinazione G12404 del 23.09.2024

1.12 MB

1.12 MB
Apri pdf
Determinazione G09633 del 19.07.2024

1.17 MB

1.17 MB
Apri pdf
Determinazione G08270 del 21.06.2024-1

1.08 MB

1.08 MB
Apri pdf
Determinazione G06541 del 30.05.2024

687.42 KB

687.42 KB
Apri pdf
Determinazione G04786 del 24.04.2024 liusta di aprile

979.05 KB

979.05 KB
Apri pdf
Determinazione G4163 del 12.04.2024

1.33 MB

1.33 MB
Apri pdf
1260-REG-1706698203462-Determinazione G01020 del 31.01.2024

905.32 KB

905.32 KB
Apri pdf
Determinazione G17172 del 20.12.2023

1.09 MB

1.09 MB
Apri pdf
Determinazione G14223 del 27.10.2023

1.09 MB

1.09 MB
Apri pdf
Lazio Region Determination No. G12613 of 25.09.2023 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 15 September 2023 - [ IT ]

907.57 KB

907.57 KB
Apri pdf
Region Determination No. G02007 of 16.02.2023 - List of drugs for which patent coverage has expired and related reference prices - Transparency list of 15 February 2023 - [ IT ]

822.53 KB

822.53 KB
Apri pdf
Lazio Region Determination No. G00741 of 23.01.2023 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 16 January 2023 - [ IT ]

1.06 MB

1.06 MB
Apri pdf
Lazio Region Determination No. G18258 of 21.12.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 15 December 2022 - [ IT ]

1.08 MB

1.08 MB
Apri pdf
Lazio Region Determination No. G16206 of 23.11.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 15 November 2022 - [ IT ]

923.63 KB

923.63 KB
Apri pdf
Lazio Region Determination No. G14527 of 25.10.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of October 2022 - [ IT ]

1.09 MB

1.09 MB
Apri pdf
Lazio Region Determination No. G12673 of 23.09.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 20 September 2022 - [ IT ]

1.12 MB

1.12 MB
Apri pdf
Lazio Region Determination No. G11038 of 11.08.2022 - Drugs payable by the National Health Service - NHS pursuant to Law 648/96. update of AUGUST 2022 - [ IT ]

776.49 KB

776.49 KB
Apri pdf
Lazio Region Determination No. G009641 of 21.07.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 20 July 2022 - [ IT ]

910.67 KB

910.67 KB
Apri pdf
Lazio Region Determination No. G07981 of 20.06.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 15 June 2022 - [ IT ]

11.64 MB

11.64 MB
Apri pdf
Lazio Region Determination No. G06150 of 18.05.2022 - List of drugs whose patent coverage has expired and related reference prices - Transparency list of 16 May 2022 - [ IT ]

914.36 KB

914.36 KB
Apri pdf
Lazio Region Determination No. G05811 of 12.05.2022 - Imports, withdrawals, withdrawals from the market, re-marketing of medicines - AIFA communications summary published on the website of the Lazio Region in the first quarter of 2022 - [ IT ]

811.64 KB

811.64 KB
Apri pdf
Lazio Region Determination No. G05800 of 12.05.2022 - Drugs payable by the National Health Service - NHS pursuant to Law 648/96, updated in May 2022 - [ IT ]

810.45 KB

810.45 KB
Apri pdf
01-sheet-reporting-drugs-for-operators - [ IT ]

892.95 KB

892.95 KB
Apri pdf
02-IVD-incident-miss-incident-sheet - [ IT ]

182.47 KB

182.47 KB
Apri pdf
03-reporting-claim-medical-devices - [ IT ]

45.01 KB

45.01 KB
Apri pdf
04-sheet-incident-miss-incident-DM - [ IT ]

170.87 KB

170.87 KB

Last Updated: 02/10/2023

Pubblicato il: 22/03/2022

Report error on this page